Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal Irinotecan in Combination with Sintilimab in Second-Line Treatment of Progressive Gastric Cancer, a Single-Arm, Single-Center, Open-Label, Phase II Clinical Study

NCT06697366 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT06697366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06697366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal Irinotecan in Combination with Sintilimab in Second-Line Treatment of Progressive Gastric Cancer, a Single-Arm, Single-Center, Open-Label, Phase II Clinical Study
Lead sponsor
Ruijin Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 20, 2024
Completion date
November 20, 2026
Enrollment
27 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer